Immupharma Plc Stock Return On Equity
| IMM Stock | 3.34 0.06 1.76% |
ImmuPharma PLC fundamentals help investors to digest information that contributes to ImmuPharma PLC's financial success or failures. It also enables traders to predict the movement of ImmuPharma Stock. The fundamental analysis module provides a way to measure ImmuPharma PLC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ImmuPharma PLC stock.
ImmuPharma |
ImmuPharma PLC Company Return On Equity Analysis
ImmuPharma PLC's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current ImmuPharma PLC Return On Equity | -1.11 |
Most of ImmuPharma PLC's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ImmuPharma PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, ImmuPharma PLC has a Return On Equity of -1.112. This is much lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The return on equity for all United Kingdom stocks is notably higher than that of the company.
ImmuPharma Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ImmuPharma PLC's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ImmuPharma PLC could also be used in its relative valuation, which is a method of valuing ImmuPharma PLC by comparing valuation metrics of similar companies.ImmuPharma PLC is currently under evaluation in return on equity category among its peers.
ImmuPharma Fundamentals
| Return On Equity | -1.11 | |||
| Return On Asset | -0.43 | |||
| Operating Margin | 36.15 % | |||
| Current Valuation | 13.95 M | |||
| Shares Outstanding | 416.44 M | |||
| Shares Owned By Insiders | 53.93 % | |||
| Shares Owned By Institutions | 26.98 % | |||
| Price To Book | 5.26 X | |||
| Price To Sales | 60.75 X | |||
| Gross Profit | (69.96 K) | |||
| EBITDA | (3.03 M) | |||
| Net Income | (2.92 M) | |||
| Total Debt | 1.67 M | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (1.36 M) | |||
| Earnings Per Share | (0.01) X | |||
| Target Price | 5.0 | |||
| Beta | 2.59 | |||
| Market Capitalization | 14.83 M | |||
| Total Asset | 2.72 M | |||
| Retained Earnings | (64.08 M) | |||
| Working Capital | (321.92 K) | |||
| Net Asset | 2.72 M |
About ImmuPharma PLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ImmuPharma PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ImmuPharma PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ImmuPharma PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in ImmuPharma Stock
ImmuPharma PLC financial ratios help investors to determine whether ImmuPharma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ImmuPharma with respect to the benefits of owning ImmuPharma PLC security.